Tuesday, Harmony Biosciences (NASDAQ:HRMY) announced the acquisition of Epygenix Therapeutics, adding a rare epilepsy franchise to its expanding late-stage pipeline of central nervous system (CNS) assets. Under the terms of the definitive agreement, Harmony paid $35 million in cash with the potential for payments of up to $130 million based on development and regulatory milestones.  In addition, there are potential payments of up to $515 million if certain sales milestones are achieved. “The acquisition of Epygenix gives us three distinct CNS franchises in late-stage development, each with a potential US peak sales opportunity of $1B-$2B,” said Jeffrey M. Dayno, M.D., President and Chief Executive Officer at Harmony Biosciences.  “We have been ...